EPIRUS Biopharmaceuticals, Inc. announced that in connection with the bankruptcy filing, the Chapter 7 trustee will assume control over the assets and liabilities of the Company. Accordingly, on July 25, 2016, all of the Company's directors have resigned from their positions as directors of the Company. As of such date, the directors of the Company were Mark H.N. Corrigan, M.D., J. Kevin Buchi, Daotian Fu, Ph.D., Geoffrey Duyk, M.D., Ph.D., William Hunter, M.D., Julie McHugh and Scott Rocklage, Ph.D. who also concurrently resigned from his position as the Company's Chief Executive Officer.